SCHEMBL31472525

SCHEMBL31472525

N#Cc1cccc(-c2ccc3[nH]nc(-c4nc5ccccc5[nH]4)c3c2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 7/20 0.71
CDK4 P11802 3/20 0.58
CCNA2 P20248 3/20 0.58
CCND1 P24385 3/20 0.58
CDK2 P24941 3/20 0.58
CCND3 P30281 3/20 0.58
JAK2 O60674 1/20 0.58
JAK1 P23458 1/20 0.58
TYK2 P29597 1/20 0.58
JAK3 P52333 1/20 0.58
FGFR1 P11362 1/20 0.57
FLT1 P17948 1/20 0.57
CHEK1 O14757 1/20 0.57
ITK Q08881 2/20 0.51
WNT1 P04628 2/20 0.51
TGFBR1 P36897 1/20 0.51
CLK2 P49760 1/20 0.51
CLK3 P49761 1/20 0.51
DYRK1A Q13627 1/20 0.51
MAP3K8 P41279 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25418501 1.00 PDPK1 (0.71) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL17801048 0.93 PDPK1 (0.62) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL5952338 0.91 PDPK1 (0.59) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL1225637 0.88 PDPK1 (0.67) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL5508118 0.86 PDPK1 (0.74) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL17801060 0.85 PDPK1 (0.60) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL3533024 0.83 PDPK1 (0.73) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL5510140 0.83 CDK4 (0.83) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL3533531 0.81 FGFR1 (0.66) PDPK1CDK4CCNA2CCND1CDK2
SCHEMBL5951956 0.81 FGFR1 (0.66) PDPK1CDK4CCNA2CCND1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES INC 2025-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS DYRK2, DYRK1A, DYRK1B PDPK1 61/4885CDK4 1402/4885CCNA2 2038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.